Importance
Recent epidemiologic and therapeutic advances have transformed
understanding of the role of and therapeutic approach to patent foramen
ovale (PFO) in ischemic stroke. Patent foramen ovale is likely
responsible for approximately 5% of all ischemic strokes and 10% of
those occurring in young and middle-aged adults.
Observations
Randomized clinical trials have demonstrated that,
to prevent
recurrent ischemic stroke in patients with PFO and an
otherwise-cryptogenic index ischemic stroke,
PFO closure is superior to
antiplatelet medical therapy alone; these trials have provided some
evidence that, among medical therapy options, anticoagulants may be more
effective than antiplatelet agents.
Conclusions and Relevance
These new data indicate a need to update classification
schemes of causative mechanisms in stroke, developed in an era in which
an association between PFO and stroke was viewed as uncertain. We
propose a revised general nomenclature and classification framework for
PFO-associated stroke and detailed revisions for the 3 major stroke
subtyping algorithms in wide use.
No comments:
Post a Comment